loading
Precedente Chiudi:
$5.11
Aprire:
$5.1
Volume 24 ore:
282.16K
Relative Volume:
0.63
Capitalizzazione di mercato:
$304.30M
Reddito:
-
Utile/perdita netta:
$-44.80M
Rapporto P/E:
-6.8133
EPS:
-0.75
Flusso di cassa netto:
$-30.67M
1 W Prestazione:
-2.11%
1M Prestazione:
-2.29%
6M Prestazione:
+50.29%
1 anno Prestazione:
+51.63%
Intervallo 1D:
Value
$4.95
$5.2184
Intervallo di 1 settimana:
Value
$4.95
$5.58
Portata 52W:
Value
$2.71
$6.5476

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Nome
Aldeyra Therapeutics Inc
Name
Industria
Biotechnology (3)
Name
Telefono
781-761-4904
Name
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Dipendente
9
Name
Cinguettio
@aldeyraaldx
Name
Prossima data di guadagno
2024-11-18
Name
Ultimi documenti SEC
Name
ALDX's Discussions on Twitter

Confronta ALDX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALDX
Aldeyra Therapeutics Inc
5.11 304.30M 0 -44.80M -30.67M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.11 106.13B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
733.59 80.61B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
649.26 38.82B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
240.55 31.03B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.15 29.28B 3.30B -501.07M 1.03B -2.1146

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-04-03 Aggiornamento Oppenheimer Perform → Outperform
2024-04-02 Ripresa H.C. Wainwright Buy
2022-04-27 Ripresa H.C. Wainwright Buy
2021-02-08 Iniziato H.C. Wainwright Buy
2020-12-16 Iniziato Berenberg Buy
2020-10-30 Iniziato Jefferies Buy
2020-10-16 Iniziato BTIG Research Buy
2020-09-22 Iniziato Alliance Global Partners Buy
2020-05-12 Iniziato Oppenheimer Outperform
2018-12-04 Iniziato Citigroup Buy
2018-09-26 Reiterato Cantor Fitzgerald Overweight
2018-09-13 Iniziato Janney Buy
2018-01-26 Iniziato Seaport Global Securities Buy
2016-09-26 Iniziato H.C. Wainwright Buy
2016-07-01 Iniziato Stifel Buy
2015-07-01 Iniziato Canaccord Genuity Buy
2015-03-25 Iniziato Chardan Capital Markets Buy
2015-03-20 Reiterato H.C. Wainwright Buy
2014-11-18 Iniziato H.C. Wainwright Buy
2014-06-19 Iniziato Aegis Capital Buy
Mostra tutto

Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie

pulisher
Jan 05, 2025

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Bought by Barclays PLC - Defense World

Jan 05, 2025
pulisher
Jan 04, 2025

Geode Capital Management LLC Has $6.01 Million Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Jan 04, 2025
pulisher
Dec 31, 2024

3 US Penny Stocks With Market Caps Over $80M To Watch - Simply Wall St

Dec 31, 2024
pulisher
Dec 30, 2024

State Street Corp Purchases 16,188 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Dec 30, 2024
pulisher
Dec 28, 2024

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Dec 28, 2024
pulisher
Dec 26, 2024

Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation - The Bakersfield Californian

Dec 26, 2024
pulisher
Dec 26, 2024

Aldeyra, UnitedHealth Group Incorporated, Blue Ridge - GlobeNewswire

Dec 26, 2024
pulisher
Dec 26, 2024

Aldeyra Therapeutics: Key Inflection Point Ahead (NASDAQ:ALDX) - Seeking Alpha

Dec 26, 2024
pulisher
Dec 23, 2024

4 Stock-ing Stuffers for Under $10 a Share - TheStreet

Dec 23, 2024
pulisher
Dec 20, 2024

High Growth Tech Stocks To Watch In December 2024 - Simply Wall St

Dec 20, 2024
pulisher
Dec 20, 2024

BNP Paribas Financial Markets Acquires 10,201 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Dec 20, 2024
pulisher
Dec 17, 2024

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Sold by Verition Fund Management LLC - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? - MSN

Dec 16, 2024
pulisher
Dec 16, 2024

Aldeyra stock retains Outperform rating on strong DED drug outlook By Investing.com - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Aldeyra stock retains Outperform rating on strong DED drug outlook - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Down 12.3% in November - Defense World

Dec 16, 2024
pulisher
Dec 15, 2024

Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Drops By 12.3% - MarketBeat

Dec 15, 2024
pulisher
Dec 11, 2024

Objective long/short (ALDX) Report - Stock Traders Daily

Dec 11, 2024
pulisher
Dec 08, 2024

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Jacobs Levy Equity Management Inc. - MarketBeat

Dec 08, 2024
pulisher
Dec 03, 2024

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Increase in Short Interest - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

Aldeyra Therapeutics CEO to Present at Citi Healthcare Conference Ophthalmology Panel - StockTitan

Dec 02, 2024
pulisher
Nov 28, 2024

Final Deadline Alert: ALDX Investor Alert: Contact Bronstein, Ge - GuruFocus.com

Nov 28, 2024
pulisher
Nov 25, 2024

Eagle Asset Management Inc. Lowers Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat

Nov 25, 2024
pulisher
Nov 23, 2024

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN

Nov 23, 2024
pulisher
Nov 23, 2024

Aldeyra announces FDA acceptance of resubmitted reproxalap application - MSN

Nov 23, 2024
pulisher
Nov 20, 2024

Top US Penny Stocks To Watch In November 2024 - Simply Wall St

Nov 20, 2024
pulisher
Nov 20, 2024

Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 - Reuters.com

Nov 20, 2024
pulisher
Nov 19, 2024

Aldeyra Therapeutics (ALDX) Refiles NDA for Innovative Dry Eye Drug Reproxalap - GuruFocus.com

Nov 19, 2024
pulisher
Nov 19, 2024

5,578 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Bought by US Bancorp DE - Defense World

Nov 19, 2024
pulisher
Nov 19, 2024

BTIG sets shares target with buy rating on Aldeyra, cites FDA read - Investing.com

Nov 19, 2024
pulisher
Nov 18, 2024

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application - MarketWatch

Nov 18, 2024
pulisher
Nov 18, 2024

FDA reviews Aldeyra's dry eye disease drug candidate By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Aldeyra announces FDA acceptance of resubmitted reproxalap application (NASDAQ:ALDX) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

FDA reviews Aldeyra's dry eye disease drug candidate - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

What is Leerink Partnrs' Forecast for ALDX FY2024 Earnings? - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Research Analysts Issue Forecasts for ALDX FY2028 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Aldeyra Therapeutics CEO to Present at Jefferies London Healthcare Conference | ALDX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Aldeyra Therapeutics Insiders Who Sold Avert US$58m Market Cap Dip - Simply Wall St

Nov 14, 2024
pulisher
Nov 14, 2024

Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 13, 2024

Nephrotic Syndrome Drugs Market Analysis of the Competitive - openPR

Nov 13, 2024
pulisher
Nov 12, 2024

Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Nov 12, 2024
pulisher
Nov 08, 2024

(ALDX) Trading Advice - Stock Traders Daily

Nov 08, 2024

Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.13
price down icon 0.08%
$22.19
price up icon 0.05%
$366.61
price up icon 1.18%
$43.17
price down icon 9.17%
biotechnology ONC
$177.88
price up icon 1.59%
$122.15
price down icon 3.73%
Capitalizzazione:     |  Volume (24 ore):